1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
M1 Kliniken AG

M1 Kliniken AG

MKLNF
M1 Kliniken AGUS flagOther OTC
11.73
USD
- -
- -
214.81MMarket Cap
M1 Kliniken AG
MKLNF
(Other OTC)

Recent

price

11.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
1.53
2.33
2.4
3.07
3.88
4.41
8.59
16.02
14.52
16.1
17.27
Revenue per Share
0.31
0.44
0.33
0.38
0.39
0.56
0.37
0.45
0.22
0.52
0.82
Basic EPS, GAAP
- -
- -
0.46
-0.09
0.03
-0.38
0.44
0.73
0.97
0.35
1.5
Free Cash Flow per Basic Share
- -
- -
0.3
0.29
0.29
0.3
0.01
0.08
0.09
0.1
0.47
Dividend per Share
1.67
1.94
1.97
2.15
2.12
2.3
2.56
2.9
3.03
3.55
3.92
Book Value per Share
0.76
1.45
1.47
2.54
3.3
3.42
4.14
4.05
4.21
2.84
2.38
Tangible Book Value per Share
15
15
15
15
17
18
19
20
20
20
20
Basic Weighted Avg Shares
23
35
36
47
65
77
160
315
285
316
339
Sales/Revenue/Turnover
6.29
18.81
12.14
12.09
9.81
10.12
5.94
3.86
3.14
4.63
7.68
Operating Margin (%)
- -
- -
- -
- -
1
3
4
6
6
5
5
Depreciation Expense
5
7
5
6
7
10
7
9
4
10
16
Net Income, GAAP
5.07
2.07
8.76
21.43
18.31
23.66
15.41
24.57
30.91
29.06
32.35
Effective Tax Rate (%)
19.92
18.99
13.93
12.24
10.14
12.6
4.28
2.83
1.51
3.25
4.72
Profit Margin (%)
-3
16
15
26
39
45
64
67
70
52
40
Working Capital
1
- -
- -
- -
- -
9
9
8
10
8
7
LT Debt
25
30
30
47
64
68
115
140
143
143
134
Total Equity
- -
22.42
13.14
11.35
9.19
8.18
7.68
6.49
3.95
6.51
11.32
Return on Invested Capital (%)
- -
24.53
17.1
18.41
19.2
22.92
9.71
7.51
1.82
8.51
13.76
Return on Capital (%)
- -
24.48
17.07
18.46
19.24
25.64
15.54
17.01
7.41
15.89
21.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.34%
17.29%
-6.29%
Free Cash Flow
- -
31.9%
334.57%
Net Income, GAAP
24.01%
28.6%
55.91%
Sales/Revenue/Turnover
35.52%
42.52%
7.23%
Total Cash Common Dividend
- -
296.19%
369.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
316
2024
- -
- -
- -
- -
339
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.52
2024
- -
- -
- -
- -
0.82
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.1
2024
- -
- -
- -
- -
0.47
2025
- -
- -
- -
- -
- -
Similar Companies
Healthcare Services Group, Inc. (HCSG)
Unihealth Hospitals Ltd. (UNIHEALTH.NS)
Fresenius SE & Co. KGaA (FRE.DE)
Fortis Healthcare Limited (FORTIS.BO)
Family Care Hospitals Ltd. (FAMILYCARE.BO)
AfroCentric Investment Corporation Limited (ACT.JO)
Business
M1 Kliniken AG M1 Kliniken AG operates as a leading provider of aesthetic medicine and plastic surgery services through its Beauty segment, offering minimally invasive and surgical treatments including breast augmentation, eyelid lifts, liposuction, abdominoplasty, nose corrections, wrinkle treatments, lip enhancements, and injections with hyaluronic acid and botulinum toxin; it also manages specialist centers under the M1 Med Beauty and Schlossklinik brands, as well as the M1 Schlossklinik in Berlin featuring six operating theaters and 35 beds. Through its Trade segment, conducted via subsidiary HAEMATO AG, the company sells pharmaceuticals and medical products for oncology, HIV/AIDS, neurology, rheumatology, chronic diseases, and aesthetic medicine, alongside brands such as M1 Select and M1 Aesthetics marketed to private customers, doctors, pharmacies, and wholesalers. Founded in 2007 and headquartered at Gruenauer Strasse 5 in Berlin, Germany, M1 Kliniken employs over 350 staff and more than 100 specialized doctors, performing over 400,000 procedures annually across more than 35 centers primarily in Germany, with international operations in Austria, Switzerland, the Netherlands, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. In recent developments, HAEMATO AG, an 85%-owned subsidiary, signed an agreement in October 2025 to sell its wholly-owned HAEMATO Pharm GmbH trading unit to the PHOENIX group pending antitrust approvals, enabling M1 Kliniken to sharpen its focus as a pure-play medical aesthetics provider; the company reported Q3 2025 revenue growth of 6.7% to EUR 274.3 million year-to-date and Q1 2025 sales up 9.6% with EBIT surging 70%, alongside management changes including the departure of Kilian Brenske in June 2024 and confirmation of long-term growth targets.